Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 9/20 | 0.43 |
| ▸ | HRH1 | P35367 | 9/20 | 0.43 |
| ▸ | FPR3 | P25089 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17313875 | 1.00 | USP2 (0.43) | USP2HRH2HRH1FPR3FPR2 | |
| SCHEMBL17313892 | 0.94 | HRH2 (0.39) | USP2HRH2HRH1FPR3FPR2 | |
| SCHEMBL17313891 | 0.94 | HRH2 (0.39) | USP2HRH2HRH1FPR3FPR2 | |
| SCHEMBL26040761 | 0.84 | HRH2 (0.49) | USP2HRH2HRH1CHRM3DPP7 | |
| SCHEMBL17313872 | 0.81 | DPP7 (0.49) | HRH2HRH1CHRM3DPP7GNAI3 | |
| SCHEMBL17313869 | 0.81 | DPP7 (0.49) | HRH2HRH1CHRM3DPP7GNAI3 | |
| SCHEMBL17313867 | 0.81 | DPP7 (0.49) | HRH2HRH1CHRM3DPP7GNAI3 | |
| SCHEMBL24324302 | 0.81 | DPP7 (0.38) | DPP7 | |
| SCHEMBL17313870 | 0.80 | DPP7 (0.50) | HRH2HRH1CHRM3DPP7GNAI3 | |
| SCHEMBL17313871 | 0.80 | DPP7 (0.50) | HRH2HRH1CHRM3DPP7GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2017-02-09 | — | — | US | claimed |
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2015-12-10 | — | — | US | claimed |
| US-9822083-B2 | Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof | BIOCELLCHALLENGE (FR) | 2017-11-21 | — | — | US | disclosed |
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2017-02-09 | — | — | US | disclosed |
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | ABCB4, SLC47A2, SLC47A1 | USP2 2981/4885HRH2 3417/4885HRH1 3050/4885 |
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | ABCB4, SLC47A2, SLC47A1 | USP2 2981/4885HRH2 3417/4885HRH1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.